Currently, BC classification and choice of treatment still depend on immunohistochemical (IHC) analysis of markers among which ER, PR and HER2 are fundamental to define Triple Negative BC (TNBC) tumors as ER-, PR- and HER2-. Here, PGR is linked to breast cancer.